Question 1

Am I eligible for this trial based on my cancer type and previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this combination treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

Question 5

What will happen if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. clinical trial (NCT06660511). Contact the study team or your healthcare provider for specific answers.

What this study is about